Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04868838 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Daratumumab to Treat Active Lupus Nephritis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from Sep 2026 to Jan 2027 Primary completion date changed from estimate of Sep 2026 to Aug 28, 2026 · Eligibility criteria expanded, about 20 words · Secondary endpoints: details revised at 3 of 5 entries Show 3 more changesShow less
    • Primary completion date changed from estimate of Sep 2026 to Aug 28, 2026
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 3 of 5 entries
  2. Re-verified, no change to tracked fieldsv10
  3. Primary and study completion dates: Jul 2026 to Sep 2026v9
  4. Trial status: Recruiting to Active, Not Recruiting Site details revisedv8 Show 1 more changeShow less
    • Site details revised
  5. Primary completion date: May 2024 to Jul 2026 Completion date: Sep 2024 to Jul 2026 · Site contact updatedv7 Show 2 more changesShow less
    • Completion date: Sep 2024 to Jul 2026
    • Site contact updated
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: May 2023 to May 2024 Completion date: Sep 2023 to Sep 2024v6 Show 1 more changeShow less
    • Completion date: Sep 2023 to Sep 2024
  2. Site contact updatedv5
  3. Primary completion date: May 15, 2023 to May 2023 Completion date: Sep 4, 2023 to Sep 2023v4 Show 1 more changeShow less
    • Completion date: Sep 4, 2023 to Sep 2023
  4. Site contact updatedv3
  5. Primary endpoints revised (2) Secondary endpoints revised (5)v2 Show 1 more changeShow less
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mayo Clinic
1,019 trials monitored
See 121 trials at risk
Lupus (SLE)
651 trials monitored
See 25 trials at risk
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.
Trial Details
NCT Number NCT04868838
Lead Sponsor Mayo Clinic
Conditions Lupus Nephritis
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov